Surgery Websites
Hepatobiliary & Pancreatic Surgery »  Meet the Team »  Hepatology »  Marion G. Peters, M.D.
Marion G. Peters, M.D.

Marion G. Peters, M.D.

Professor, Department of Medicine
John V. Carbone, M.D., Endowed Chair in Medicine
Chief of Hepatology Research

Contact Information

Appointments: (415) 353-2318
marion.peters@ucsf.edu
Open Popup

Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
St. Vincent's Hospital Medical School, Melbourne, Australia, Medicine
Melbourne University, M.D., 1991, Medicine/Immunology

  • 1973-76 Resident and Registrar in Internal Medicine, St.Vincent's Hospital, Melbourne, Australia
  • 1976-77 Clinical Research Registrar to Dr. I. R. Mackay, Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
  • 1977-78 Gastroenterology Registrar, St. Vincent's Hospital, Melbourne, Australia
  • 1978-80 Clinical Research Fellow in Hepatology to Dr. T. B. Reynolds, University of Southern California, Los Angeles, CA
  • 1980-83 Visiting Fogarty Fellow to Dr. A.S. Fauci, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD
  • 1983-85 Visiting Staff Fellow to Liver Diseases Section, National Institute of Arthritis,  Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD
  • American Board of Internal Medicine, Internal Medicine
  • UCSF Liver Center
  • Member, UCSF Immunology Graduate Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Liver Injury and Repair
  • Viral hepatitis and the role of the host immune response.

Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.

Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.

My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the  predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.

We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.

 

Data provided by UCSF Profiles, powered by CTSI
  • UCSF Liver Center
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 1985
    -
    May 2023
    Co-Investigator
  • NRSA Hepatology Training Grant
    Sponsor:
    Sponsor ID:
    Funding Period:
    Dec 2001
    -
    Jun 2022
    Co-Principal Investigator
  • HIV status and reproductive aging affect liver fibrosis in HIV/HCV infected women
    Sponsor:
    Sponsor ID:
    Funding Period:
    Mar 2010
    -
    Feb 2013
    Principal Investigator
  • General Clinical Research Center
    Sponsor:
    Sponsor ID:
    Funding Period:
    Dec 1974
    -
    Mar 2009
    Co-Investigator
  • HCV &ALCHOOL-- EPIDEMIOLOGY &HOST-VIRUS CORRELATES
    Sponsor:
    Sponsor ID:
    Funding Period:
    Sep 2000
    -
    Jul 2006
    Principal Investigator
  • INTESTINAL IMMUNE RESPONSE INFLAMMATORY BOWL DISEASE
    Sponsor:
    Sponsor ID:
    Funding Period:
    Sep 1995
    -
    Aug 2001
    Principal Investigator
  • INTESTINAL IMMUNE RESPONSE IN INFLAMMATORY BOWEL DISEASE
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jun 1991
    -
    Oct 1995
    Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 185
Data provided by UCSF Profiles, powered by CTSI
  1. Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson I. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol. 2021 Jul 27. View in PubMed
  2. Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V, North American AIDS Cohort Collaboration on Research, Design of IeDEA . Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. Hepatology. 2021 Sep; 74(3):1190-1202. View in PubMed
  3. French AL, Grennan D, Daubert E, Seaberg EC, Peters M, Augenbraun M, Fischl M, Kassaye S, Franco R, Kuniholm M, Adimora AA, Workowski K, Weber KM. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women. AIDS. 2021 07 15; 35(9):1433-1438. View in PubMed
  4. Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD, North American AIDS Cohort Collaboration on Research and Design of IeDEA . Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512. View in PubMed
  5. Peters MG, Kottilil S, Terrault N, Amara D, Husson J, Huprikar S, Florman S, Sulkowski MS, Durand CM, Luetkemeyer AF, Rogers R, Grab J, Haydel B, Blumberg E, Dove L, Emond J, Olthoff K, Smith C, Fishbein T, Masur H, Stock PG. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. Am J Transplant. 2021 05; 21(5):1780-1788. View in PubMed
  6. View All Publications

 

Site Directory
    X